A new mechanism to inhibit proteasomes, protein complexes that are a target for cancer therapy, is the topic of an article published in the journal Chemistry & Biology.
Why some sickle cell patients do not adhere to available treatment
9/12/2014
Experiencing discrimination because of their race or health condition can influence just how much trust people put into the health profession.
Ovarian cancer metastasis promoted by mesothelial cells
9/12/2014
Less than half of the women diagnosed with ovarian cancer will survive beyond 5 years.
Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the...
Ethnic disparities in cancer and genetic mutations linked
9/12/2014
One of the goals of genome sequencing is to identify genetic mutations associated with increased susceptibility to disease.
Early diagnosis and detection rates of skin cancer boosted by pioneering digital application
9/11/2014
The early diagnosis and detection rates of skin cancer has been boosted by a pioneering digital application developed at the University of Edinburgh which trains the medical profession to...
Olaparib tablet safe in pretreated ovarian cancer patients
9/11/2014
An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better...
Early diagnosis and detection rates of skin cancer boosted by pioneering digital application
9/11/2014
The early diagnosis and detection rates of skin cancer has been boosted by a pioneering digital application developed at the University of Edinburgh which trains the medical profession to...
Researchers unlock the genetic code of cancer-causing liver fluke parasite
9/11/2014
An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis...
Olaparib tablet safe in pretreated ovarian cancer patients
9/11/2014
An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better...